Drugs / PBF-677
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02639975 | Dec 2015 → Apr 2016 | glaucoma | Palobiofarma SL | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03773952 | Jul 2018 → May 2021 | ulcerative colitis | Palobiofarma SL | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2021-11-10 | Palo Biofarma, S.L | Results November 10th. 2021. Palobiofarma announces positive results in the Phase IIa clinical trial evaluating it´s first in class investigational treatment PBF-677 in patients with mild to moderate ulcerative colitis. palobiofarma.com ↗
The trial achieved statistical significance in all the efficacy parameters measured despite the limited number of patients enrolled. |
All press releases naming this drug 2 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PBF-677 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03773952 ↗ |
| Action | Inhibit | “antagonist of Adenosine A3 receptor (AA3R)” NCT03773952 ↗ |
| Modality | Small molecule | “oral small molecule” NCT03773952 ↗ |
| Route | Oral | “once daily oral administration” NCT02639975 ↗ |